Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM712 (CONQUER) in neovascular AMD
NCT05345769Phase 1Completed
- Sponsor
- AffaMed Therapeutics
- Start
- Apr 2022
- Primary completion
- Nov 2024
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASKG712 in neovascular age-related macular degeneration (NVAMD), sponsored by AffaMed Therapeutics. Primary endpoints: Incidence of ocular adverse events of the study eyes at 252 days, Incidence of non-ocular AEs at 252 days and 2 more. Started Apr 2022; status: completed.
02
Drugs
ASKG712
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05345769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05345769.